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Abstract
A better understanding of human papillomavirus (HPV) infection in men is an essen‐
tial component of prevention programs aimed to reduce cervical cancer and other HPV-
related diseases. A screening test capable of detecting asymptomatic/subclinical genital
HPV infection in men at a reasonable price and causing minimal discomfort to the patient
would be very valuable. The following chapter focuses on acetowhite test usefulness in
the detection of asymptomatic/subclinical genital high-risk (HR) HPV infection in high-
risk men populations, HR-HPV prevalence in sexually active healthy male partners of
women  diagnosed  of  high-grade  cervical  intraepithelial  neoplasia  and  genotype-
specific concordance between partners, addressing the preventive strategies that would
reduce HPV infection in men. We present data from 125 men, sexual partners of women
with preneoplastic cervical lesions. Prevalence of HR-HPV infection in male was high (50,
24% HPV16) and genotype concordance within the 60 infected couples was remarkable
(62% shared at least one genotype). Acetowhite (AW) test was positive in 27% patients,
showing low sensitivity for the identification of HR-HPV infection but allowed the
diagnosis of subclinical HPV-related lesions in more than 10%. Current smoking and
genital warts were associated with an increased risk of HR-HPV infection in men (OR: 2.4
and 5.6, respectively).
Keywords: human papillomavirus DNA test, prevention, prevalence, cervical intrae‐
pithelial neoplasia, male, mass screening, genital warts, diagnosis
1. Introduction
Human papillomavirus (HPV) infections are one of the most common sexually transmitted
infections worldwide [1], representing a significant health problem due to their high preva‐
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lence and transmissibility. HPVs are a very large family of double-stranded DNA viruses
(dsDNA), very resistant that can survive in the environment without a host and is able to infect
humans. These viruses are not classified as serotypes, but as genotypes on the basis of DNA
sequence. Currently, over 120 genotypes have been identified and about 40 genotypes (the alpha
genus) can be transmitted through sexual contact and infect the anogenital  region. HPV
genotypes have been classified into low-risk genotypes, associated with anogenital warts, low-
grade cervical lesions and recurrent respiratory papillomatosis, and high-risk genotypes (HR-
HPV) [1] (Table 1), which eventually can lead to malignant transformation. HR-HPV are strongly
associated with cancer and high-grade neoplasia of the anogenital tract, including the anus
(AIN), penis (PeIN), uterine cervix (CIN), and vulva (VIN), and also a proportion of orophar‐
yngeal cancer [2]. Although these infections are typically transient and asymptomatic, some of
them will result in anogenital warts, and dysplastic and/or neoplastic lesions, which cause a
substantial disease burden in both sexes and generate a considerable economic distress within
society [3].
IARC classification HPV genotypes
HR-HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59
pHR-HPV 26, 34, 53, 66, 67, 68, 69, 70, 73, 82
Classification of oncogenic HPV genotypes detected in this work.
IARC, International Agency for Research on Cancer; HR-HPV, high-risk HPV genotypes; pHR, probable/possible high-
risk genotypes.
Table 1. Oncogenic HPV genotypes.
The virus may remain inactive for a long time and produce asymptomatic infection of the skin.
It can be transmitted from one individual to another directly (by sexual contact) or indirectly.
The dynamics of heterosexual transmission of HPV are still being investigated [4].
About one-third to one-quarter of invasive penile cancers (Alemany et al.) and nearly 99.7%
of cervical cancer worldwide and in 96.8% of cervical preneoplastic and neoplastic lesions in
our community (Perez et al.) may be related to HPV according to the retrospective studies.
Although rare, penile cancer is associated with a high morbidity and mortality. The carcino‐
genesis of penile cancer is thought to involve two pathways: one related to inflammation and
other dermatological conditions of the penis, and other related to HPV infection (López-
Romero et al.). HPV DNA prevalence in invasive penile cancer varied geographically, with
the highest prevalence in Oceania (55.6%), North America (48.7), Africa (36.8%), South America
(39.7%), and Europe (45.9%), being the most common HR-HPV types: HPV16 (30.8%) and
HPV18 (6.6%) [5]. So that, it is important to be cautious and not to consider overall prevalence
as universal because the role of HPV in penile cancer etiology could be strongly influenced by
histologic distribution and geographic region as it is also true for other HPV malignancies such
as vulvar and head and neck cancers [6].
Genital warts (GWs) represent a significant public health problem associated with clinical
symptoms (burning, bleeding, and pain) and psychosocial problems (embarrassment, anxiety,
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and decreased self-esteem). Several studies have suggested that the occurrence of genital warts
has been increasing over time [7]. Approximately 65% of people who have sex with an infected
partner will develop warts themselves [8].
There has been immense progress in understanding the natural history of HPV infection in
women disease. HPV is the primary cause of cervical cancers. Recently, there has been an
interest in understanding the relationship between HPV infection and disease in men [9]. The
male sexual partner`s role and in his partner’s genital warts or high-grade cervical intraepi‐
thelial neoplasia (CIN II, CIN III-Ca in situ) lesions is also undefined. The diagnosis of most
cutaneous and external genital wart (GW) can be made on clinical examination or with AW
test and biopsy. In case of genital intraepithelial neoplasia, determining the extent of diseases
is essential.
2. HR-HPV transmission among sexual partners
Epidemiological studies show that the HR-HPV infection is necessarily the sexual transmitted
cause of invasive cervical cancer in women and its precursor lesion, cervical intraepithelial
neoplasia (CIN) [10].
Direct genital mucosa contact during sexual intercourse is the principal route of HPV trans‐
mission [11]. About 80% of newly sexual couples will develop HPV-related lesions within 3
years after commencing sexual activity, most of whom will spontaneously regress within 1–2
years or until the age of 30–35 years [12]. The biology and dynamics of HPV transmission
among sexual partners is still a cause for debate and has not already been completely estab‐
lished. Models have shown that HPV transmissibility is substantially higher than that of other
viral sexually transmitted pathogens [13], but data on the natural history of HPV transmission
between heterosexual partners are limited. Many studies [14–17] analyzed the prevalence and
genotypes of high-risk infections of the foreskin before first sexual intercourse found asymp‐
tomatic infection in 12–83.3% [14, 16], speculating that non-sexual routes play significant roles
in HPV transmission. In this regard, HPV transmission may occur upon contact with infected
towels or other objects. In contrast to these findings, Pilatz et al. [15] did not find HPV in the
foreskin of boys.
Despite the recommendation of the guidelines on sexually transmitted diseases, investigation
of the presence of HPV in men who are sexual partners of infected woman has not been agreed.
Previous studies suggested that the cancer of the penis and cervix may share the same
etiological factor(s), because significant numbers of invasive cervical cancer were detected in
partners of patients with penile cancer [18, 19]. It was assessed the contribution of the males’
genital HPV DNA status to the risk of development of cervical neoplasia in their sexual
partners, confirming that men could be vectors of HPV types typically observed in cervical
cancer [20]. However, another studies did not confirm the findings of these investigators [21].
As the process of HPV infection can take more than 15 years, the current partner could not be
necessarily the source of infection.
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3. HR-HPV prevalence in heterosexual men populations
HPV infection causes substantial morbidity and its incidence is similar in both genders. The
ongoing HPV in men study (HIM) provides the most current data on HPV infection and lesion
development in men [9, 22–24]. Assessing HPV prevalence in men and investigating the
sources of variation are essential for understanding the epidemiology of HPV infection.
The pooled HPV in the general population is significantly higher (20.4–36.3%) [25, 26] in
studies published after 2000 (8.8%) [27]. The lower pooled prevalence in earlier publications
might therefore be due to the detection method used and potentially not to a change in HPV
prevalence over time. Age-specific prevalence curves among men are flatter [19, 28, 29] in
contrast to the pattern observed in women [30]. The prevalence of genital infection in men does
not differ significantly among age groups as it does in females [30]. In general population, HPV
infection has a consistently higher prevalence within the penile epithelium of asymptomatic
men than within the cervix of women with normal cytological testing [29].
Several factors have been suggested to influence HPV prevalence, varying substantially
between sampling sites, techniques [31, 32], and different populations [33]. HPV prevalence is
higher when samples are collected from a greater number of anatomic sites [29]. Hebnes et al.
[27] in meta-analysis of studies examining HPV prevalence among men found a wide hetero‐
geneity between general and high-risk populations. HIV-positive men, men with sexually
transmitted infection and male sexual partners of women with HPV, CIN, CIS, or invasive
cervical cancer are considered a high-risk population [34, 35]. Number of types tested for varies
between articles. In studies reporting prevalence estimates for more than one HPV type, the
commonest detected types were HPV16 [20, 24, 26, 27, 36, 37] and HPV18 [27].
From a socio-epidemiological standpoint, it is important to note that HPV-infected men play
a key role in the transmission of the HPV virus to their female sexual partners. The range
reported in other studies for sexual partners of women with CIN was 30–68% [19, 24, 26, 36,
38]. Geographical region, anatomical sampling site, or HPV detection methods have not
explained the wide heterogeneity of results [27]. In contrast, Franceschi et al. [39] showed the
strongest variation by countries, with a higher prevalence of HPV infection among Brazilian
sexual partners of woman with CIN compared with those detected in other countries (Colom‐
bia, Mexico, Spain).
The natural course of disease in men by establishing rates of acquisition and time to clearance
of HPV infection has not been investigated properly. Although fewer data of infection duration
have been reported in men, findings suggest that HPV infection clear more quickly for men
than for women and that men have similar duration of infection for oncogenic and non-
oncogenic types [7, 28]. Mean clearance time, defined as time to elimination of 50% of all
infections, was estimated to be 5.9 months (patridge JM). HPV infections in women tend to
have a longer duration and are estimated to clear at average of 12.2 months [40].
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4. Concordance between sexual partners
Positive concordance is defined as both partners having the HPV outcome of interest. HPV
concordance in heterosexual couples has important clinical and public health implications. In
terms of HR-HPV detection, the percentage of couples harboring HR-HPV was 32–65% [28,
36, 37, 41]. In couples where both members were HPV positive, more than 60% were infected
with one or more of the same HPV types. This level of concordance was observed independ‐
ently of HPV prevalence and is consistent with the high transmissibility of HPV [25, 28, 36, 38,
41]. Studies over the past 20 years evaluating HPV infection concordance among heterosexual
partners have shown many inconsistencies, reporting concordances of type-specific infection
between 2 and 87% [20, 42–44]. Such heterogeneous findings may be due to diverse laboratory
DNA detection techniques, methods for study population selection and different anatomical
sites sampling, among other factors [25].
Positive concordance was usually higher for female partners of men with HPV infection than
for male partners of women with HPV infection. Men with HPV-positive female partners had
one or more of the same HPV types more often in studies that recruited men with HPV-related
diseases compared with studies without this inclusion criterion for men (65.8 vs. 27.2%) [28].
These findings suggest that the epithelial cells of the penile skin are more resistant to HPV
infection than the cervical epithelium and the duration of HPV infection is shorter in men than
in women [28, 38].
5. Acetowhite test versus molecular detection of HR-HPV infection
Infection with one or more of the 40 HPV detected at the genitals is common among men aged
18–70 years. Only 5% of these HPV infections progressed to an external genital lesions during
follow-up. There were observed substantially higher rates of progression for certain HPV types
[45].
Most genital infections in men are asymptomatic, detectable only by viral DNA testing and
become undetectable over time. Subclinical lesions, including those related with HR-HPV
types, are more than 10 times common than clinical (apparent) infection and are identified on
examination after application of acetic acid solution, a procedure known as acetowhite test
(AW test, peniscopy). Since the American Society for Colposcopy and Cervical Pathology
recommended the use of HPV DNA testing for the triage and management of women with
atypical squamous cells of undetermined significance result of Pap test, an increasing number
of female patients are requesting HPV DNA testing for their partners. Although the current
gold standard for HPV genotyping is a genetic sequencing targeting the product of gene
amplification (Heidegger), a screening test capable of detecting asymptomatic and subclinical
genital HPV infection in men at a reasonable price and causing minimal discomfort to the
patient would be very valuable.
To date, economic data have primarily focused on the more common HPV-related cervical
cancer and its precursor lesions, as well as the benign, very common condition of genital warts.
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Nevertheless, available data indicate that HPV-related disease is associated with a significant
economic burden in males. Specifically, in men, the total direct cost of HPV infection acquired
through the age of 24 years was estimated at 62 million dollars per year, the comparable figure
for women being 2.8 billion [46].
Studies of the psychosocial effects of HPV-related disease in males are lacking. However, there
is a significant psychosocial burden reported in women being screened for, or diagnosed, with
HPV-related disease [47].
The currently available methods for evaluating HPV infection in male are HPV DNA test and
AW test [12]. This is full description of our study procedures: The entire penis and scrotum of
the patient were examined under magnification, and the presence of genital warts was
recorded. After this examination, we sprayed them with 5% acetic acid solution. After 5 min,
we enhanced the visualization of the skin by a colposcope under fourfold and sevenfold
magnification, respectively. AW lesions were classified as typical for the presence of well-
demarcated lesions with a slightly elevated border and the occurrence centrally of punctuated
capillaries with or without an associated epithelial depression (Groove) and non-typical for
the presence of lesions exhibiting a ragged border and lacking punctuated capillaries. Regard‐
less of AW test result, the specimen for HPV DNA detection was obtained. Samples were taken
with three cytobrushes from the preputial cavity (the inner part of the foreskin, the glans and
the sulcus coronarius, scrotum, and urethral meatus) rotated 360 grades and suspended
together into one single vial containing TE buffer pH 8.0 Molecular Biology grade (AppliChem
GmbH, Darmstadt, Germany). Samples were maintained at 2–8°C and processed within 24–
72 h after collection. The brushings were collected without spraying the genital region with
saline solution. DNA was isolated using QIAamp MinElute Media Kit (Qiagen, Hilden,
Germany). Extracted nucleic acids were stored at −20°C. An aliquot of the original sample was
also stored at −20°C. Amplification and detection were carried out using the Linear Array HPV
Genotyping Test (Linear Array. Roche Diagnostics, Mannheim, Germany) according to the
manufacturer’s instructions. We described the distribution of 22 HPV genotypes classified as
HR (HR-HPV, IARC Group 1 carcinogens) or probable/possible HR (pHR-HPV, IARC Group
2A/B carcinogens) by the International Agency for Research on Cancer Monograph Working
Group (Table 1). This test also detects human beta-globin in order to test the adequate sample
cellularity and absence of inhibitors. Linear Array does not have individual probe for HPV52
but uses a probe that simultaneously detects HPV52, HPV33, HPV35 and HPV58. Additional
specific PCR was performed in case of HPV33, HPV35 and/or HPV58 infection in order to
properly detect confections of these three genotypes with HPV52 [48].
In our study, around 30% of positive AW results were not related with HR-HPV infection [49–
51]. False-positive results may be due to low-risk HPV infection or inflammatory conditions,
common in patients with sexually transmitted diseases [52]. Nevertheless, the need for
detecting subclinical genital HPV infection, associated with detectable AW lesions [53], has
been emphasized and these population would need follow-up or biopsy. Afonso et al. [37]
found that 50% of sexual partners of women with CIN harbored HPV in lesions and these were
predominantly subclinical. The diagnosis and treatment of acetowhite lesions in men do not
seem to alter or improve the progress of the squamous intraepithelial lesions in their female
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partners [54]. Nevertheless, these acetowhite lesions on male genitalia are in fact squamous
intraepithelial alterations and should not be left due to the risk of their further development
[37] as Sudenga et al. [45]. have presented the first estimates of genital HPV infection progres‐
sion to PeIN. They are the first authors that follow these HPV infections and their progress to
lesion in men. We encourage the importance of the clinical follow-up of this men and perhaps
of taking a biopsy afterwards, in case of HPV infection persistence.
Problems associated with screening techniques in men include inadequate collection of cells
for the detection of HPV DNA by use of swabs and brushes, poor specificity, and patient
discomfort during peniscopy. When lesions are not visible, sampling at multiple penile sites
could increase the sensitivity of the HPV [41, 55]. In addition, the use of acetic acid and a
colposcope requires specific training, clinical experience, and significant costs associated with
the procedure and training. Polymerase chain reaction (PCR) has emerged as the most sensitive
available method for the detection of latent HPV infection. The infectious diseases literature
supports the lack of the US Food and Drug Administration (FDA) approval of HPV tests for
HPV detection in men and the absence of adequate therapy for established HPV infection in
this population.
6. Our results of HPV prevalence in a high-risk population of heterosexual
men and concordance between heterosexual partners
A cross-sectional study was conducted by the Urology Department of the University Hospital
of Vigo, Spain, from January 2013 to June 2015 (López Díez et al., Enf Infecc Microbiol Clin,
2016 in press). We recruited 125 asymptomatic men, aged 18 years, whose SP (sexual partner,
regular sexual intercourse for more than 1 year) had presented high-grade squamous cervical
lesions (CIN grade 2 or CIN grade 3-carcinoma in situ) in the previous 6 months. Prevalence
of HR-HPV infection in men was 50.4% (63/125). Multiple HR-HPV infections were detected
in 30.4% (38/125) of this population. Data of HPV genotype were available in 120 women.
HPV16 was the most frequent genotype, detected in 47.6% (30/63) of infected men and 67.5%
(81/120) women (Table 2). HR-HPV infection was detected in both partners in 50% (60/120).
Among these infected couples, 62% (37/60) harbored at least one genotype in common. The
HPV16-specific concordance was as follows: 41.7% (25/60) couples were concordantly HPV16
positive and 18.3% (11/60) were concordantly HPV16 negative (Kappa value: 0.21).
The proportion of women with the same genotype as their male partner was 58.7% (37/63).
The proportion of men sharing the same genotype as their female partner was 30.8% (37/120),
p < 0.0001.
AW procedure was positive in 34/125 (27.2%) patients. AW procedure showed 25.4% (95% CI
13.8–36.9) sensitivity, 71.0% (95% CI 58.9–83.1) specificity, 47.1% (95% CI 28.8–65.3) positive
predictive value and 48.3% (95% CI 37.5–59.2) negative predictive value for the identification
of HR-HPV infection (Table 3). AW lesions and HR-HPV were detected at the same time in
16/125 (12.8%) males.
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IARC classification Genotype Infected
men (n)
Global prevalence
(N = 125) %
Prevalence in
HPV-positive men
(N = 63) %
HR-HPV HPV16 30 24.0 47.6
HPV18 4 3.2 6.3
HPV31 9 7.2 14.3
HPV33 2 1.6 3.2
HPV39 6 4.8 9.5
HPV45 5 4.0 7.9
HPV51 11 8.8 17.5
HPV52 12 9.6 19.0
HPV56 8 6.4 12.7
HPV58 3 2.4 4.8
HPV59 6 4.8 9.5
pHR-HPV HPV53 13 10.4 20.6
HPV66 10 8.0 15.9
HPV67 1 0.8 1.6
HPV68 2 1.6 3.2
HPV69 1 0.8 1.6
HPV70 4 3.2 6.3
HPV73 3 2.4 4.8
HR-HPV, high-risk HPV genotypes; pHR, probable/possible high-risk genotypes; IARC, International Agency for
Research on Cancer.
Crude HPV prevalence calculated in 63 HPV-positive patients: 25 single and 38 multiple infections (López Díez et al.,
Enf Infecc Microbiol Clin, 2016 in press).
Table 2. Type-specific HPV prevalence in men.
HR-HPV DNA detection
Yes No
n (%) n (%) p OR (95% CI)
AW lesion Yes 16 (25.4) 18 (29.0) 0.648 0.83 (0.38–1.83)
No 47 (74.6) 44 (71.0) – –
Genital lesions detected by peniscopy in asymptomatic sexual partners of women with high-grade cervical lesions,
according to the presence of HR-HPV.
HR-HPV DNA, high-risk HPV; AW, acetowhite test; OR, odd ratio; 95% CI, confidence interval.
Statistically significant, p < 0.05 (chi-square test).
Table 3. Acetowhite lesions according to HR-HPV DNA detection.
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Genital warts were present in 17/125 (13.6%) patients. AW procedure showed sensitivity 82.3
(95% CI 55.8–95.3), specificity 81.4% (95% CI 72.6–88.6), positive predictive value 41.1% (95%
CI 25.1–59.1) and negative predictive value 96.7% (95% CI 89.9–99.1) for genital warts’
detection (Table 4).
Genital warts
Yes No
n (%) n (%) p OR (95% CI)
AW lesion Yes 14 (82.3) 20 (18.5) <0.0001 20.53 (5.39–78.27)
No 3 (17.6) 88 (81.5) – –
AW: Acetowhite test, OR: odd ratio, 95% CI: confidence interval.
Statistically significant, *p < 0.05 (chi-square test).
Table 4. Acetowhite lesions according to genital warts’ detection.
HR-HPV prevalence was 6/15 (40.0%) in circumcised men and 57/110 (51.8%) in not circum‐
cised men (p > 0.05).
7. Risk factors for HR-HPV prevalence in men
Coexistence of non-oncogenic and oncogenic HPV-types is frequent [56, 57], which may itself
predispose to cancer. A Danish study of 50,000 people with GW found an elevated risk of HPV-
associated cancers in people with GW compared with the general population [56]. Although
test for the presence of HPV are not recommended for the diagnosis of GW [58] in our study,
the AW test was sensitive and specific for genital warts’ detection, showing a high negative
predictive value. This procedure could avoid missing small clinical lesions. They are generally
regarded as a benign condition not associated with mortality, but they can be difficult to treat
and recurrence is often observed. Visible warts represent only the tip of the iceberg, and low-
and high-risk HPV infections contribute to the genital lesion burden in men [24]. Healthcare
providers should have a higher suspicion for HPV-associated cancers in immunocompromised
patients with GW. AW test can be helpful in the diagnosis of GW. In particular, soaking acetic
acid into suspicious lesions can enhance the degree of suspicion in lesions without classic
features. Taking a biopsy might also be indicated if diagnosis is uncertain, the lesions do not
respond to standard therapy or the disease worsens during therapy [58].
Limited data exist on the association between HPV infection and smoking in men. In this study,
current smoking could increase 2.3-fold the risk of HPV-prevalent infection in males, as found
in the HIM study. At present, it is unclear how smoking may influence HPV infection in men,
but many possible mechanisms exist. Smoking could potentially increase viral load by
weakening the cellular immune response [59].
Diagnosis and Prevalence of High-Risk Human Papillomavirus Infection in Heterosexual Men
http://dx.doi.org/10.5772/62948
157
Sexual behavior has been strongly associated with HPV infection and seropositivity in men
[60]. Features previously associated with HR-HPV were as follows: young age at first sexual
intercourse (FSI), a higher number of lifetime sexual partners (LSP) and a higher number of
recent SP. Contradictory results about the influence of lifetime number of SP were reported
[26, 41, 55, 61, 62]. This data could be attributable not only to the range of birth year of men
but also to geographical characteristics [27, 33]. In Western population, the numbers of lifetime
sexual partners in men and women are both relatively high, and little gender difference could
be observed. Burchell et al. reported that the proportion of ≥5 lifetime sexual partners was
64.4% for men, in line with our results (55.2% in men).
The risk of having one or more SP in the preceding year was has been poorly evaluated. The
risk of HPV re-infection between a monogamous couple is still a matter of debate [63]. In
contrast, Rombaldi et al. [64] and Parada [25] found a high association between both variables.
In the National Questionnaire of Sexual Health, published by Spanish Government in 2009, it
was found that the mean age of FSI was 17–18 years (29.3%) for Spanish men. In our study,
younger age at FSI was not a risk factor for HPV infection as other authors have previously
reported [27, 64]. There are contradictory data that could be attributable not only to the range
of birth year of men but also to geographical characteristics [55, 60].
Similar to other studies [55, 65], we did not find the expected protective effect of circumcision
on HPV acquisition. Circumcision seems to be associated with reduced persistence in men [66]
even though the mechanism of protection is unclear. Removal of the foreskin could minimize
the chance of acquisition of new infections or could result in an increased clearance of
preexisting infections [28, 67]. Our different results could be due to the fact that circumcision
is not very common in our geographical area and that analysis could not assess specific
associations in the glans penis, the area expected to be most likely protected by removal of the
foreskin [68].
8. HR-HPV risk factors found in our study
Epidemiological characteristics of the studied high-risk population are shown in Table 5.
Current smoking status was associated with an increased risk of HR-HPV infection in men:
38.2% (21/55) versus 60% (42/70), OR 2.3 (95% CI 1.1–4.7), p = 0.016.
Variable HPV detection (n = 125) p-value
Positive Negative Bivariate analysis Multivariate analysis
Age at FSI 16.9 ± 2.7 17.4 ± 2.4 0.382
Lifetime SP
 1–5 SP 10 (34.5%) 19 (65.5%) 0.050
 >5 SP 53 (55.2%) 43 (44.8%)
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Variable HPV detection (n = 125) p-value
Positive Negative Bivariate analysis Multivariate analysis
Recent SP
 1 SP 51 (49.0%) 53 (51.0%) 0.498
 >1 SP 12 (57.1%) 9 (42.9%)
Current smoking
 Yes 42 (60.0%) 28 (40.0%) 0.015* 0.016* (OR 2.3, 95% CI 1.1–4.7)
 No 21 (38.2%) 34 (61.8%)
CIN grade in partner
 CIN 2 30 (54.5%) 25 (45.5%) 0.411
 CIN 3-CIS 33 (47.1%) 37 (52.9%)
FSI, first sexual intercourse;, SP, sexual partners; CIN, cervical intraepithelial neoplasia; CIS: carcinoma in situ.
Age was expressed as mean ± standard deviation.
* p < 0.05, statistically significant.
Table 5. HPV detection in men according to epidemiological characteristics.
Prevalence of HR-HPV infection was 14/17 (82.4%) in patients with genital warts versus 49/108
(45.4%) in patients without genital warts (OR 5.6, 95% CI 1.5–20.7, p = 0.008) (Figure 1).
Figure 1. Statistically significant, *p< 0.05 (chi-square test).
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9. Prevention of HPV infection in men
Until recently, no highly effective primary prevention strategy to reduce the risk of HPV
acquisition existed. However, research has demonstrated that nonavalent, quadrivalent and
bivalent HPV vaccines stimulate immunogenicity in males and females [69]. On October 16,
2009, the FDA approved the use of quadrivalent vaccine in males aged 9–26 years for the
prevention of genital warts. Subsequently, the Advisory Committee on immunization
Practices (ACID) declined to recommend the quadrivalent vaccine for routine immunization
in men [70], providing a permissive recommendation in this age range for HPV vaccination.
Most European countries offer HPV vaccination for girls, but vaccine recommendations for
boys are warranted. HPV vaccination of girls will in theory also benefit the male population
through herd immunity.
Uninfected sexual partners may be an important target population for HPV vaccination [71].
Potential interventions such as a therapeutic HPV vaccine may avert new HPV infections.
Moreover, vaccinating boys would reduce HPV-related diseases in both sexes to a greater
extent than herd immunity, which depends on high vaccination rates among females.
The benefits of vaccination to individuals seronegative to HPV types included in the vaccine
are clear, and emerging studies suggest that HPV vaccine may also help people who previously
had and cleared an infection [72] although additional researches in this population are needed.
While prophylactic HPV vaccine does not have substantial impact on established infection, it
may have cross-protection against non-vaccine genotypes [73]. However, if these vaccines
could also be successful in lowering the HPV load, they may also assist in lowering transmis‐
sion [13].
There is no direct evidence for protection by HPV vaccines against penile cancer because penile
cancer is so rare that there could never be a clinical trial large enough to measure the effect [74].
HPV vaccines have not been around long enough to measure the population impact on penile
cancer. However, the observed HPV type distribution reinforces the potential benefit of current
and new vaccines in reduction in HPV-related penile neoplasia lesions [6].
Future trials of HPV vaccines in men should take into account not only the presence of penile
HPV infection but also the presence of penile subclinical lesions as an outcome measure for
the efficacy of a vaccine. More complex study designs would also allow researchers to better
understand first transmission, reinfection and back and forth passage within couples, con‐
cordance in couples in which one partner has received HPV vaccine and concordance after
treatment for HPV-related lesions is an essential component of prevention programs aimed to
reduce cervical cancer and other HPV-related diseases in men and women.
10. Final considerations
HPV causes cancer in both men and women. The HPV-related cancer burden remains higher
in women than men, even in countries that have effective cervical cancer screening programs.
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It is clear that males have poor knowledge of HPV infection, morbidity, transmission, and
prevention. Moreover, several issues are controversial and should be addressed by adopting
a multidisciplinary and multiprofessional approach. Regardless of vaccination strategies
adopted, efforts should be made to educate males about HPV and its health implications.
Currently, there is no licensed test for HPV detection in men and there are no recommendations
for male screening. Although routine HPV testing is not necessary for men in general popu‐
lation, findings from emerging research in high-risk population suggest that HPV infection is
pervasive and persistent in these groups, warranting the adoption of additional screening and
prevention policies. Our findings suggest the need for greater attention to sexual partners of
HPV-infected individuals. Male sexual partners of female with high-grade lesions should be
referred for evaluation and combined peniscopy, and HPV DNA test will ensure accurate
detection of HPV status among males. Female partners of men with HPV-related diseases
should be encouraged to get screened for HPV-related disease given that they have a high
likelihood of concomitant infection and that most infection in couples are of the same viral
type. Screening may also benefit male partners of HPV-infected women. Interventions that
study the true prevalence of HPV infection in asymptomatic men and try to reduce HPV-
associated penile lesions could be important to both men and women.
Further prospective and controlled studies in different populations are needed to provide
adequate counseling to men that demand to know whether they are infected by HR-HPV.
Long-term follow-up will contribute to the knowledge about the influence of persistent HPV
infection in male and the potential recurrence of his sexual partner after treatment. We assume
that the faster way to achieve greatest protection for cervical cancer and its precursors is to
vaccinate males as well as female because both genders contribute to the transmission of HPV
infection.
The prevention, diagnosis, and treatment of HPV-associated diseases in men will reduce the
disease burden not only in males, but also in females, and help destigmatize the focus of the
HPV-related disease on women.
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